Literature DB >> 8603945

Human granulocytic ehrlichiosis in Wisconsin and Minnesota: a frequent infection with the potential for persistence.

J S Dumler1, J S Bakken.   

Abstract

Human granulocytic ehrlichiosis (HGE) is a tickborne illness caused by an agent closely related to Ehrlichia equi and Ehrlichia phagocytophila. The clinical presentation is nonspecific, and diagnosis is made infrequently. Sixty-six sera were obtained from 54 patients in Minnesota and Wisconsin with undifferentiated fever during the summer and fall of 1993. Serologic reactivity with E. equi was observed in 6 (11%), including 4 seroconversions, 1 stable titer, and 1 seroreversion. Of the seropositive patients, HGE agent DNA was detected by polymerase chain reaction in the first serum from 4 of 5 patients and was present in the serum of 1 of 2 untreated patients after 21 days, even when E. equi antibodies also were present. HGE is a significant and potentially frequent cause of undifferentiated fever in Wisconsin and Minnesota during seasons with tick activity. The agent may persist in untreated patients for at least 1 months or may be cleared earlier, even if not treated with doxycycline or tetracycline.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603945     DOI: 10.1093/infdis/173.4.1027

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Serological responses to Ehrlichia equi, Ehrlichia chaffeensis, and Borrelia burgdorferi in patients from New York State.

Authors:  S J Wong; G S Brady; J S Dumler
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

Review 2.  Human granulocytic anaplasmosis.

Authors:  Johan S Bakken; J Stephen Dumler
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

3.  Comparison of the nucleotide sequences of 16S rRNA, 444 Ep-ank, and groESL heat shock operon genes in naturally occurring Ehrlichia equi and human granulocytic ehrlichiosis agent isolates from Northern California.

Authors:  J S Chae; J E Foley; J S Dumler; J E Madigan
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Outcome of diagnostic tests using samples from patients with culture-proven human monocytic ehrlichiosis: implications for surveillance.

Authors:  J E Childs; J W Sumner; W L Nicholson; R F Massung; S M Standaert; C D Paddock
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

5.  Clinical and serological follow-up of patients with human granulocytic ehrlichiosis in Slovenia.

Authors:  S Lotric-Furlan; T Avsic-Zupanc; M Petrovec; W L Nicholson; J W Sumner; J E Childs; F Strle
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

6.  Serologic and molecular detection of granulocytic ehrlichiosis in Rhode Island.

Authors:  M T Yeh; T N Mather; R T Coughlin; C Gingrich-Baker; J W Sumner; R F Massung
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

7.  Outcomes of treated human granulocytic ehrlichiosis cases.

Authors:  Alan H Ramsey; Edward A Belongia; Craig M Gale; Jeffrey P Davis
Journal:  Emerg Infect Dis       Date:  2002-04       Impact factor: 6.883

8.  Expression of members of the 28-kilodalton major outer membrane protein family of Ehrlichia chaffeensis during persistent infection.

Authors:  Jian-zhi Zhang; Hong Guo; Gary M Winslow; Xue-jie Yu
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

9.  Diagnosis of human ehrlichiosis by PCR assay of acute-phase serum.

Authors:  J A Comer; W L Nicholson; J W Sumner; J G Olson; J E Childs
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

10.  Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States.

Authors:  Max Maurin; Johan S Bakken; J Stephen Dumler
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.